[HTML][HTML] The NLRP3 and pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases

C de Torre-Minguela, P Mesa del Castillo… - Frontiers in …, 2017 - frontiersin.org
Inflammasomes are multiprotein complexes that critically control different aspects of innate
and adaptive immunity. Among them we could highlight the release of pro-inflammatory …

[HTML][HTML] Familial Mediterranean fever: recent developments in pathogenesis and new recommendations for management

S Özen, ED Batu, S Demir - Frontiers in immunology, 2017 - frontiersin.org
Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory
disease (AID) affecting mainly the ethnic groups originating from Mediterranean basin. The …

[HTML][HTML] Canakinumab for the treatment of autoinflammatory recurrent fever syndromes

F De Benedetti, M Gattorno, J Anton… - … England Journal of …, 2018 - Mass Medical Soc
Abstract Background Familial Mediterranean fever, mevalonate kinase deficiency (also
known as the hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor …

Cytokine networking of innate immunity cells: a potential target of therapy

I Striz, E Brabcova, L Kolesar, A Sekerkova - Clinical science, 2014 - portlandpress.com
Innate immune cells, particularly macrophages and epithelial cells, play a key role in
multiple layers of immune responses. Alarmins and pro-inflammatory cytokines from the IL …

Anakinra for colchicine‐resistant familial Mediterranean fever: a randomized, double‐blind, placebo‐controlled trial

I Ben‐Zvi, O Kukuy, E Giat, E Pras, O Feld… - Arthritis & …, 2017 - Wiley Online Library
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10–
20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1 …

Colchicine in clinical medicine. A guide for internists

G Cocco, DCC Chu, S Pandolfi - European journal of internal medicine, 2010 - Elsevier
Colchicine (COL) has been used in medicine for a long time. It is well recognized as a valid
therapy in acute flares of gouty arthritis, familial Mediterranean fever (FMF), Behçet's …

An update on familial Mediterranean fever

M Lancieri, M Bustaffa, S Palmeri, I Prigione… - International Journal of …, 2023 - mdpi.com
(1) Background: Familial Mediterranean Fever (FMF) is the prototypal autoinflammatory
disease, characterized by recurrent bursts of neutrophilic inflammation.(2) Methods: In this …

Rilonacept for colchicine-resistant or-intolerant familial Mediterranean fever: a randomized trial

PJ Hashkes, SJ Spalding, EH Giannini… - Annals of internal …, 2012 - acpjournals.org
Chinese translation This article has been corrected. The original version (PDF) is appended
to this article as a Supplement. Background: Currently, there is no proven alternative therapy …

Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature

U Meinzer, P Quartier, JF Alexandra, V Hentgen… - Seminars in arthritis and …, 2011 - Elsevier
OBJECTIVES: Familial Mediterranean fever (FMF) is an autosomal-recessive
autoinflammatory disorder common in Mediterranean populations. FMF is associated with …

Evidence-based recommendations for the practical management of Familial Mediterranean Fever

V Hentgen, G Grateau, I Kone-Paut, A Livneh… - Seminars in arthritis and …, 2013 - Elsevier
Abstract Aim Familial Mediterranean Fever (FMF) is the most common recurrent
autoinflammatory fever syndrome. Still, many issues—eg: colchicine dosage adjustment …